毛囊淋巴瘤患者的间歇性肺部变化和持续的COVID-19:一个病例报告
Makiko Yomota1, Masaru Tanaka2, Takayuki Kobayashi1
1Department of Respiratory Medicine Tokyo Metropolitan Komagome Hospital Tokyo Japan.
Respirology case reports
|February 21, 2024
概括
本案例研究详细介绍了长期冠状病毒疾病2019 (COVID-19) 和卵泡淋巴瘤患者的间歇性肺部变化. 用皮质类固醇和免疫抑制剂治疗导致康复,突出显示了潜在的治疗方法.
科学领域:
- 肺部病理学 肺部病理学
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
背景情况:
- 长期冠状病毒疾病2019 (COVID-19) 可能导致严重的呼吸道并发症.
- 免疫功能低下的患者,如正在接受治疗的卵泡淋巴瘤患者,风险更高.
- 间歇性肺病是持续性COVID-19的严重后果.
研究的目的:
- 报告COVID-19和毛囊淋巴瘤患者间歇性肺部变化的病例.
- 在免疫功能低下的患者中研究长期COVID-19相关肺炎的组合疗法的疗效.
- 强调对严重的COVID-19后果的治疗策略的需要.
主要方法:
- 一个患有卵泡淋巴瘤的患者接受Rituximab和Bendamustine的病例报告.
- 患者患有长期的COVID-19与间歇性肺部变化.
- 治疗涉及皮质类固醇和免疫抑制剂的组合.
主要成果:
- 在组合治疗后,患者从间歇性肺部变化中恢复过来.
- 该治疗方案在治疗长期COVID-19严重肺部并发症方面表现出有效性.
- 在免疫功能低下个体中成功管理危及生命的疾病.
结论:
- 与皮质类固醇和免疫抑制剂的联合治疗可能有效治疗长期的COVID-19引起的间歇性肺部变化.
- 这一案例强调了COVID-19在免疫功能低下患者中的潜在严重性.
- 需要进一步的研究,为这种患者群体制定治疗指南.
相关概念视频
01:29Pulmonary Tuberculosis I
243
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
243
01:27Pneumothorax-II
146
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
146
01:28Pulmonary Tuberculosis II
236
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
236
01:20COPD: Pathogenesis and Clinical Features
273
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
273
01:29Pneumonia II: Pathophysiology
272
The pathophysiology of pneumonia involves the following steps:
272